WE’RE XPEDITE DIAGNOSTICS. THIS IS OUR STORY. OUR IMPACT.
We aim to bring molecular diagnostics to the point-of-care with fast, accurate, and accessible nucleic acid extraction – empowering researchers and clinicians with efficiency and precision.
Our vision
Transforming disease diagnostics by making molecular testing accessible at the point-of-care. We aim to close the gap in healthcare with faster, more reliable, and cost-effective DNA & RNA extraction solutions.
Our mission
We are committed to advancing molecular diagnostics through our proprietary groundbreaking cell capture and reverse purification technology. By simplifying and accelerating nucleic acid extraction, we aim to empower researchers, clinicians and diagnostic laboratories with efficiency, precision and accessibility in disease detection.
Streamlined protocol, minimal equipment
Nucleic acid extraction is the most neglected part of diagnostics, and we’re here to revolutionize it. Our technology eliminates the need for any complex equipment like centrifuges and minimizes the use of consumables – allowing you to perform disease diagnostics even in just a suitcase. Optimized to deliver high-quality results in minutes, accelerating molecular diagnostics with enhanced accessibility for research and point-of-care applications.
The story behind SwiftX™ technology
Dr. Andy Wende
Founder and Managing Director,
Xpedite Diagnostics GmbH
SwiftX™ rapid extraction technology is closely connected to Dr. Andy Wende, a biochemist with 15+ years of experience in research and development of molecular biology-based technologies and holder of 16 patents.
During his tenure at Qiagen, Dr. Wende contributed to various point-of-care diagnostics projects and developed several alternative nucleic acid extraction concepts and strategies to improve DNA & RNA extraction by:
-
Simplifying and shortening the workflow, enabling extraction in any laboratory, remote or point-of-care setting.
-
Reducing environmental impact, minimizing plastic usage and harmful chemicals like chaotropic salts and organic solvents.
-
Enhancing sensitivity by improving nucleic acid yield from hard-to-lyse organisms such as Mycobacteria.
When these internal point-of-care projects came to an end, Dr. Wende pivoted to join TÜV SÜD, where he became a Lead Auditor and Product Assessor for high-risk IVD medical devices under the European regulations IVDD and IVDR.
In 2020, Dr. Wende founded Xpedite Diagnostics to transform these concepts into high-quality and IVD-certified products. This led to the development of the SwiftX™ Toolbox, a suite of specialized components, designed to accelerate nucleic acid extraction.
Over the years, both the product portfolio and the team of Xpedite Diagnostics have expanded. As of early 2025, we have developed nine DNA/RNA extraction products, tailored for specific diseases and applications in research and diagnostics. Five of those products are CE-IVD certified under the IVD Regulation (EU) 2017/746. In addition, we have also designed and engineered magnetic separation racks to support our proprietary reverse purification technology for efficient extraction of nucleic acids.
Product and process quality is of high importance to us, which is why we are compliant with the international quality management standard for medical devices, ISO 13485:2016.
Fundings and Partnerships
Our journey has been supported by funding, grants and strategic partnership across academia and industry to advance innovative and efficient nucleic acid extraction chemistries and protocols. Some of our notable fundings, project grants and partners include,
- Project Kolumbus (Bavarian program for the promotion of technology-oriented start-ups ,BayTOU)
- Project “DiagnoSeps” (KMU innovative by German Federal Ministry for Research)
- Project Prepare-TID (EU Horizon program)
- Project “MoDeV” (Central Innovation Programme for SMEs)
- German Network against Neglected Tropical Diseases (DNTDs)
- Seegene
- EUROIMMUN
- QT Biotech Co., Ltd.
